Key point: ceftriaxone does not treat scrub typhus

• Empirical coverage while diagnosis is unconfirmed - scrub typhus commonly presents as undifferentiated febrile illness/sepsis, and ceftriaxone is added to cover leptospirosis, enteric fever, or bacterial sepsis until serology/PCR confirms the diagnosis.
• Documented or suspected co-infection (e.g., concurrent leptospirosis or bacteremia), which is not uncommon in endemic tropical regions.
• Severe sepsis/shock/meningoencephalitis where broad empirical antibiotics are started per sepsis protocols pending a specific diagnosis.

The actual antirickettsial regimen

• Mild/uncomplicated disease: oral doxycycline 100 mg twice daily (usual choice), or azithromycin (500 mg day 1, then 250 mg daily, or similar) as an alternative - preferred in pregnancy and children where tetracyclines are relatively contraindicated (Dermatology, 2-Vol Set 5e, p. 1664-67).
• Severe scrub typhus: Harrison's Principles of Internal Medicine (22nd ed., p. 1857-60) notes that in severe scrub typhus, the combination of doxycycline and azithromycin is beneficial compared to monotherapy of either agent, and that doxycycline/chloramphenicol-poor-responders in some regions (e.g., Thailand) respond to azithromycin plus rifampin.
• Route: doxycycline and azithromycin are typically given orally; IV formulations of doxycycline (or azithromycin) are used only if the patient cannot tolerate oral intake (e.g., altered sensorium, ileus, shock, ARDS).

Evidence check (recent literature)

• The INDOXACIN trial (Varghese et al., NEJM 2023, PMID 36856615), a multicenter RCT of IV doxycycline vs IV azithromycin vs both in severe scrub typhus, found no significant difference in the composite outcome (persistent organ dysfunction, new organ dysfunction, or death) between doxycycline alone, azithromycin alone, or the combination. So routine combination therapy is not clearly superior to monotherapy for severe disease based on this RCT.
• A 2023 systematic review/meta-analysis (Gupta et al., BMC Infectious Diseases, PMID 38110855) similarly found doxycycline and azithromycin have comparable efficacy in scrub typhus overall.

IV Doxycycline + IV Azithromycin for Severe Scrub Typhus — Administration and Safety

1. IV Doxycycline

• Reconstitute the lyophilized powder as per product insert (usually with sterile water for injection), then dilute further in 100-250 mL of 0.9% NaCl or D5W to a concentration of 0.1-1 mg/mL.
• Infuse slowly over 1-4 hours (never as a rapid bolus/push) - rapid infusion increases risk of phlebitis and hypotension.
• Protect the infusion bag from direct light during administration (tetracyclines are photolabile).
• Avoid co-infusion in the same line with calcium-, magnesium-, or iron-containing solutions (chelation reduces activity and can cause precipitation).
• Switch to oral doxycycline as soon as the patient can tolerate oral/enteral intake - bioavailability is essentially identical, so this is safe and preferred to avoid infusion-related complications and cost (Tintinalli's Emergency Medicine, p. 2818-40 makes this same point for other indications: "PO doxycycline has the same bioavailability as IV doxycycline and avoids painful infusion").

2. IV Azithromycin

• Reconstitute the vial (commonly 500 mg) with sterile water to make a 100 mg/mL solution, then further dilute in 250-500 mL of 0.9% NaCl or D5W to a final concentration of 1-2 mg/mL.
• Infuse over 1 hour minimum at 2 mg/mL, or over 3 hours if using the more concentrated 1 mg/mL preparation is not feasible — do not give as a bolus. Faster infusion markedly increases GI intolerance and local infusion-site reactions.
• Give as a dedicated line if possible; azithromycin is largely incompatible with many co-infused drugs.
• Switch to oral azithromycin once the patient is stable and tolerating oral intake — typically after 2-5 days of IV therapy, to complete a short course.

3. Putting it together in severe scrub typhus

• Both drugs can be run as separate infusions on the same day (not mixed in one line/bag). A reasonable severe-disease regimen: doxycycline 100 mg IV q12h plus azithromycin 500 mg IV once daily, reassessing at 48-72 hours.
• De-escalate to oral doxycycline and/or oral azithromycin as soon as the patient improves clinically (defervescence, resolving organ dysfunction, tolerating oral intake).
• Supportive care matters as much as the antibiotic choice in severe disease: fluid management (careful volume status - scrub typhus can cause ARDS and myocarditis, so avoid fluid overload), vasopressor support for shock, renal replacement therapy if acute kidney injury develops, and monitoring for multiorgan dysfunction (hepatic, renal, pulmonary, CNS - meningoencephalitis).
• Evidence note: The INDOXACIN RCT (Varghese et al., NEJM 2023, PMID 36856615) and a 2023 meta-analysis (Gupta et al., PMID 38110855) both found no significant outcome benefit of combining doxycycline + azithromycin over either drug alone in severe scrub typhus. So while combination therapy is commonly practiced (and reasonable when the diagnosis or local resistance pattern is uncertain), current best evidence does not mandate routine dual therapy — monotherapy with either agent is an acceptable, evidence-supported alternative, and it reduces drug burden and side-effect risk.

4. Safety Profile

• GI: nausea, vomiting, esophageal irritation/ulceration (mainly with oral tablets/capsules, so this is why the IV route is chosen in vomiting/unconscious patients).
• Photosensitivity - advise sun protection during and shortly after the course.
• Contraindicated in pregnancy and in children under 8 years for anything but short courses (tooth discoloration, enamel hypoplasia, and, in the fetus/neonate, effects on bone growth) (Fitzpatrick's Dermatology, p. 2664-80; Dermatology 2-Vol Set 5e, p. 1696).
• Hepatotoxicity, pseudotumor cerebri (benign intracranial hypertension), and rarely pancreatitis have been reported.
• Local: infusion-site phlebitis, pain - infuse slowly and dilute adequately.
• Drug interactions: reduced absorption with cations (Ca, Mg, Al, Fe, bicarbonate) - not relevant for the IV route but relevant once switched to oral; enhanced metabolism/reduced levels with enzyme inducers (rifampin, phenytoin, carbamazepine).
• No dose adjustment needed in renal impairment (doxycycline is one of few tetracyclines safe in renal failure).

• Cardiac: QT-interval prolongation and risk of ventricular arrhythmia (torsades de pointes) - use caution or avoid in patients with baseline QT prolongation, hypokalemia/hypomagnesemia, or those on other QT-prolonging drugs; a baseline/on-treatment ECG is prudent in patients with cardiac risk factors (Goldman-Cecil Medicine notes clinicians "may want to avoid...azithromycin in individuals at risk for QT-prolongation"). Some observational data also link azithromycin to increased cardiovascular death risk in high-risk patients (Cummings Otolaryngology references).
• GI: nausea, diarrhea, abdominal pain - generally milder than erythromycin.
• Hepatotoxicity - rare but reported cholestatic hepatitis.
• Ototoxicity (reversible hearing loss) with prolonged/high-dose use.
• Infusion-site reactions and phlebitis - minimized by adequate dilution and slow infusion as above.
• Generally considered safe in pregnancy and young children (an advantage over doxycycline), and dose adjustment is not routinely required in mild-moderate renal or hepatic impairment.

• Daily clinical review of fever curve, organ function (renal, hepatic, respiratory), and hemodynamics.
• Baseline ECG plus repeat if any new arrhythmia symptoms or if other QT-prolonging drugs are co-administered.
• Renal and liver function tests periodically, especially in severe/complicated disease.
• IV site inspection for phlebitis/extravasation.
• Watch for a Jarisch-Herxheimer-like reaction (transient worsening of fever/symptoms after starting effective antirickettsial therapy) in the first 24-48 hours - this is expected and not a treatment failure.

Why this combination is safe

Practical safety checklist for this combination

Bottom line

Scrub Typhus: Mild (Uncomplicated) vs Severe (Complicated) Presentation

Mild / Uncomplicated (Normal) Scrub Typhus

• Fever - abrupt onset, high-grade
• Headache - often frontal, severe
• Myalgia - generalized body aches
• Malaise and fatigue
• Cough and mild respiratory symptoms
• Gastrointestinal symptoms - nausea, vomiting, mild abdominal pain
• Eschar - a dark, crusted lesion at the site of chigger (mite) bite; classic but present in only about 50% of cases
• Regional lymphadenopathy near the eschar, sometimes generalized
• Maculopapular rash - trunk-predominant, may spread to extremities; seen in a minority of patients
• Splenomegaly
• Atypical lymphocytes on blood counts

Severe / Complicated Scrub Typhus

• ARDS (acute respiratory distress syndrome) - respiratory failure, often requiring mechanical ventilation
• Acute kidney injury - a well-documented complication, ranging from mild azotemia to dialysis-requiring renal failure
• Hypotensive/septic shock
• Meningoencephalitis - altered sensorium, seizures, neurological signs
• Myocarditis and cardiac dysfunction
• Hepatic dysfunction - jaundice, transaminitis, occasionally fulminant hepatitis
• Disseminated intravascular coagulation (DIC) and bleeding manifestations
• Multiorgan failure/toxemia - the terminal common pathway; Tintinalli's Emergency Medicine notes "death occurs from multiorgan toxemia within 1 to 2 weeks of illness onset if untreated"

Key differentiating clues at presentation

Why this distinction matters clinically

How to Dilute Doxycycline Injection (IV)

Step 1 — Reconstitute the vial

• Take the 100 mg vial and reconstitute with 10 mL of Sterile Water for Injection (or 20 mL for a 200 mg vial) to make a 10 mg/mL stock solution.
• Swirl gently until fully dissolved — do not shake vigorously.

Step 2 — Further dilute for infusion

• Withdraw the entire reconstituted 10 mg/mL solution and add it to 100 mL–1000 mL of a compatible IV fluid, giving a final infusion concentration between 0.1 mg/mL and 1 mg/mL (most commonly ~0.5 mg/mL, e.g., 100 mg in 200 mL).
• Compatible diluents:
  • 0.9% Sodium Chloride Injection (Normal Saline)
  • 5% Dextrose Injection (D5W)
  • Lactated Ringer's Injection
  • Dextrose 5% in Lactated Ringer's
  • Ringer's Injection
  • Invert Sugar 10% in Water

Step 3 — Infuse

• Infuse slowly over at least 1 hour (never as a rapid bolus/push) — for a typical 100 mg dose at ~0.5 mg/mL, minimum infusion time is about 1 hour.
• Protect the bag and tubing from direct light throughout preparation, storage, and infusion — doxycycline is photosensitive.
• Avoid running it through the same line as calcium-, magnesium-, or iron-containing solutions — these chelate doxycycline and reduce its activity/cause precipitation.

Stability and timing (important — discard if exceeded)

Quick practical example

Doxycycline Injection: Mixing with Ascorbic Acid Ampule + Sterile Water

Why ascorbic acid is involved

General mixing sequence (verify exact volumes against the specific product insert — brands vary)

1. Prepare the acidic diluent first: Draw up the ascorbic acid ampule and add it to the sterile water for injection ampule (or vice versa, per the pack instructions), mixing gently to get a clear solution. This combined ascorbic acid + sterile water solution is your reconstitution diluent.
2. Reconstitute the doxycycline vial: Inject this ascorbic acid/sterile water mixture into the doxycycline powder vial (commonly 10 mL for a 100 mg vial), and swirl gently — do not shake vigorously — until the powder is fully dissolved into a clear solution. This gives a concentrated stock of roughly 10 mg/mL.
3. Further dilute for IV infusion: Withdraw this reconstituted 10 mg/mL solution and add it to a larger volume of a compatible IV fluid — 0.9% Sodium Chloride or 5% Dextrose, 100-1000 mL — to bring the final infusion concentration down to 0.1-1 mg/mL (commonly ~0.5 mg/mL, e.g., 100 mg diluted into a 200 mL bag).
4. Infuse slowly, over at least 1 hour, and protect the bag/tubing from direct light throughout preparation and infusion, since doxycycline degrades on light exposure.
5. Discard unused solution after the stability window has passed (typically 6-12 hours at room temperature depending on the diluent used, or up to 72 hours if refrigerated and light-protected before starting the infusion).

Important safety notes

• Once the ascorbic acid/sterile water/doxycycline mixture is reconstituted, do not add it into the same line as calcium-, magnesium-, or iron-containing fluids, or barbiturate/sulfonamide solutions — doxycycline in this acidic form can cause precipitation or reduced stability with these agents.
• Inspect the final solution visually before infusing — it should be clear and free of particulate matter or discoloration; discard if cloudy or discolored.
• The exact ampule volumes, mixing order, and diluent ratios differ by manufacturer/brand, so always follow the package insert of the specific product you have in hand — some kits specify mixing ascorbic acid with sterile water first, others specify injecting sterile water into the vial then adding ascorbic acid. If you can tell me the specific brand name on the pack, I can look up its exact reconstitution instructions.